Which letter ind - Study guides, Class notes & Summaries

CCRP SoCRA Exam Latest Update Rated A 21 CFR Part 11 Electronic Records; Electronic Signatures 21 CFR Part 11 Subpart B Electronic Records 21 CFR Part 11 Subpart C Electronic Signatures 21 CFR Part 50 Protection of Human Subjects 21 CFR Part 50 Subpart B Informed Consent of Human Subjects 21 CFR Part 50 Subpart D Additional Safeguards for Children in Clinical Investigations 21 CFR Part 56 Institutional Review Board 21 CFR Part 56 Subpart B Organization and Personnel 21 CFR Part 56 Subpa...

nightingale anatomy final questions and answers graded A+

nightingale anatomy final questions and answers graded A+ Which letter indicates the popliteal region? E Physiology is defined as the study of the _____ of a living organism. function Brainpower Read More The gluteal region is ________ to the popliteal region. superior Which letter indicates the umbilical region? B As an anatomical region, lumbar refers to the infero-medial aspect of the back. Which structure is located entirely within the right...

According to the Quality System Regulation, when an investigation of a complaint is conducted all of the following are requirements for inclusion in the record of the investigation EXCEPT: A. The dates and results of the investigation B. The nature and details of the complaint C. Changes in procedures correcting quality problems D. Any reply to the complainant - Answer-C. A regulatory affairs professional wants to schedule a pre-NDA meeting with FDA. He or she should: A. Write a letter to...

RAC EXAM QUESTIONS WITH 100% CORRECT ANSWERS A deficiency letter may be issued to a company during a Biologics License Application (BLA) review for which of the following? - Answer- Clinical testing did not include enough subjects Company X is developing marketing materials for a Class II medical device known as "Y." In one marketing piece, the company talks about the clinical data supporting the device's marketing. Which of the following statements is illegal and should NOT be inc...

CITI GCP Training Questions and Answers Graded A+ ICH E6 has broader requirements than FDA or HHS concerning confidentiality of medical records and access by third parties. If investigators are complying with ICH E6 guideline, they must: Clearly disclose to subjects in the informed consent form that the monitor, auditor, IRB/IEC, and the regulatory authorities may have access to the subject's medical records. ICH (2016) E6 Section 4.8.10(n) states that the informed consent should indicate ...

A blood sample collection is required to screen for bloodborne pathogens before subject could be enrolled in a study. Where will subjects find information of the procedures and any foreseeable risks or inconveniences? - ansICF A Clinical Research Coordinator (CRC) adjusted the dose of the Investigation Product (IP) for a subject as the subject was suffering from Adverse Events (AEs) like headaches and vomiting. When is a CRC allowed to do this task? - ansOnly when the CRC is a qualified phy...

drug - An article intended for use in the diagnosis, cure mitigation treatment or prevention of disease in man new drug - -New use of a drug substance or component (active ingredient, excipient, carrier, coating). -New use of a combination of approved drugs -Change in proportion of ingredients in a combination drug -New intended use of a drug -Change in dosage, method or duration of administration or application active moiety - Central, active part of a molecule or ion responsible for th...

RAC US Exam Prep Questions and answers solved 100% 30-day hold - ANS(aka 30-day safety review) Time frame between filing a protocol under an IND and the FDA approval to proceed with enrollment. Also, the time period between when a company submits an IND and when it can initiate a protocol. This timeline may be extended if FDA does not agree with the proposed protocol. (see "Clinical Hold.") 120-day Safety Report - ANSAmendment to an NDA containing a safety update due 120 days after the...

When is an NDA annual report due? - ANS-60 days after the anniversary date of U.S. approval of the application. NDA Reporting Period ? All Blood and HCT/P Problems - ANS-45 calendar days of Fatal/Life threateneing/Disabling/Surgical Intervention and hospitalization Reporting Period? Postmarket Device Death, Serious Injury, Malfunction - ANS-Within 30 calendar days of awareness Reporting Period? Device Special FDA, or Remedial Action to Prevent Death/Harm - ANS-Within 5 work days of aw...